Apr 20, 2021 7:00am EDT Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
Apr 05, 2021 7:00am EDT Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
Mar 30, 2021 8:00am EDT Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
Mar 25, 2021 8:29am EDT Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update
Mar 19, 2021 7:00am EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
Mar 18, 2021 7:15am EDT Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
Feb 22, 2021 7:10am EST New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
Feb 01, 2021 7:00am EST Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
